{
 "name": "晶鑽生醫",
 "slug": "tw-6815",
 "aliases": [
  "晶鑽生醫股份有限公司",
  "Diamond",
  "6815"
 ],
 "ticker": "6815",
 "industry": "生技醫療業",
 "website": "https://www.diamond-biotechnology.cc/",
 "summary": "晶鑽生醫（6815）是興櫃的生技醫療類股公司，2014 年成立，2021 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "晶鑽生醫股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "Diamond",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2021-01-29",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2014-11-26",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "謝佳憲",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "賴柏如",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 397056490,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "https://www.diamond-biotechnology.cc/",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：Meteora lifting premium（美特拉拉提線）",
   "value": "中臉提拉及輕至中度鼻唇溝｜TFDA第二類醫材新增套管線規格變更獲准｜台灣",
   "unit": "",
   "as_of": "2024-04-11",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&step=2&co_id=6815&spoke_date=20240411&spoke_time=171349&seq_no=1&TYPEK=rotc",
   "note": "發言日期2024-04-11 17:13:49；主旨：本公司研發生產之「美特拉拉提線Meteora lifting premium」，新增醫材之規格，獲得中華民國衛生福利部(TFDA)同意核准變更第二類醫材銷售許可證；序號1。許可證衛部醫器製字第007883號；只確認2024年4月變更，未把公告日當初次核准日。"
  },
  {
   "claim": "產品許可：METEORA聚對二氧環己酮（PDO）可吸收縫線",
   "value": "NMPA第三類醫療器械國械注許20253020001｜中國｜2025-01-06",
   "unit": "",
   "as_of": "2025-01-08",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&step=2&co_id=6815&spoke_date=20250108&spoke_time=170658&seq_no=1&TYPEK=rotc",
   "note": "發言日期2025-01-08 17:06:58；主旨：更正公告本公司獲得線雕線材聚對二氧環己酮(PDO)可吸收縫線產品之中國藥品監督管理局(NMPA)第三等級醫療器材許可證核准通知。；序號1。更正正文明載01/06獲批、01/07官方發佈及公司知悉；as_of用01/08更正公告日。"
  },
  {
   "claim": "管線：NeoFilera（妮芙蕾；PDLLA＋CMC）",
   "value": "鼻唇溝皺褶凹陷矯正與體積填充｜已取得TFDA第三類醫材銷售許可｜台灣",
   "unit": "",
   "as_of": "2025-03-26",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&step=2&co_id=6815&spoke_date=20250326&spoke_time=210019&seq_no=6&TYPEK=rotc",
   "note": "發言日期2025-03-26 21:00:19；主旨：本公司所研發之膠原蛋白增生「皮下填補劑妮芙蕾」取得TFDA核發第三類醫材銷售許可證(衛部醫器製字第008439號)；序號6。衛部醫器製字第008439號；來源未另列主管機關許可證落款日，不新增精確核准日期事實。"
  },
  {
   "claim": "授權合作：NeoFilera（妮芙蕾）",
   "value": "LABORATOIRES FILL-MED及GENTLEREGEN AG｜歐洲、非洲、印度、中東、俄羅斯、澳洲、紐西蘭、中國、東南亞（不含泰國）｜2025-12-20",
   "unit": "",
   "as_of": "2025-12-20",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&step=2&co_id=6815&spoke_date=20251220&spoke_time=225116&seq_no=3&TYPEK=rotc",
   "note": "發言日期2025-12-20 22:51:16；主旨：公告本公司及GENTLEREGEN AG與法國LABORATOIRES FILL-MED公司簽署授權合約；序號3。公司負責製造；正文簽署事件及契約起日同為12/20，未採官網轉載發稿日。"
  },
  {
   "claim": "已收金額（公告日為準）：NeoFilera（妮芙蕾）",
   "value": 2000000,
   "unit": "歐元",
   "as_of": "2026-01-29",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&step=2&co_id=6815&spoke_date=20260129&spoke_time=155602&seq_no=1&TYPEK=rotc",
   "note": "發言日期2026-01-29 15:56:02；主旨：公告本公司及GENTLEREGEN AG與法國LABORATOIRES FILL-MED公司簽署授權合約，收取階段里程碑達成金200萬歐元。；序號1。公告明稱「收取階段里程碑達成金」；非授權總值，亦無足夠依據另列為簽約金。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6815.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}